Hydroxyprostaglandin Dehydrogenases
"Hydroxyprostaglandin Dehydrogenases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Catalyzes reversibly the oxidation of hydroxyl groups of prostaglandins.
| Descriptor ID |
D006911
|
| MeSH Number(s) |
D08.811.682.047.820.375
|
| Concept/Terms |
Hydroxyprostaglandin Dehydrogenases- Hydroxyprostaglandin Dehydrogenases
- Dehydrogenases, Hydroxyprostaglandin
- Hydroxyprostaglandin Dehydrogenase
- Dehydrogenase, Hydroxyprostaglandin
- Prostacyclin Dehydrogenase
- Dehydrogenase, Prostacyclin
|
Below are MeSH descriptors whose meaning is more general than "Hydroxyprostaglandin Dehydrogenases".
Below are MeSH descriptors whose meaning is more specific than "Hydroxyprostaglandin Dehydrogenases".
This graph shows the total number of publications written about "Hydroxyprostaglandin Dehydrogenases" by people in this website by year, and whether "Hydroxyprostaglandin Dehydrogenases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2006 | 2 | 0 | 2 |
| 2008 | 2 | 0 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 3 | 0 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hydroxyprostaglandin Dehydrogenases" by people in Profiles.
-
Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung. Int J Clin Exp Pathol. 2013; 6(11):2419-29.
-
Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma. Int J Clin Exp Pathol. 2012; 5(4):278-89.
-
Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression. BMC Cancer. 2010 Dec 06; 10:672.
-
Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma. Int J Clin Exp Pathol. 2010 Jul 05; 3(6):608-17.
-
Differential expression of type 2 3a/type 5 17ß-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system. Int J Clin Exp Pathol. 2010 Mar 25; 3(8):743-54.
-
Developmental evaluation of aldo-keto reductase 1C3 expression in the cryptorchid testis. Urology. 2010 Jul; 76(1):67-72.
-
Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor. Int J Clin Exp Pathol. 2009 Nov 15; 3(2):147-55.
-
Tissue distribution of human AKR1C3 and rat homolog in the adult genitourinary system. J Histochem Cytochem. 2008 Sep; 56(9):853-61.
-
AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells. Mol Cell Endocrinol. 2008 Jul 16; 289(1-2):60-6.
-
Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer. 2006 Mar; 13(1):169-80.